Wells Fargo & Company Sutro Biopharma, Inc. Call Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding STRO
# of Institutions
137Shares Held
62.4MCall Options Held
77.1KPut Options Held
31.4K-
Suvretta Capital Management, LLC New York, NY7.19MShares$18.7 Million0.98% of portfolio
-
Black Rock Inc. New York, NY6.91MShares$18 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.2MShares$10.9 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3MShares$7.79 Million0.03% of portfolio
-
Bio Impact Capital LLC Cambridge, MA2.83MShares$7.36 Million1.53% of portfolio
About SUTRO BIOPHARMA, INC.
- Ticker STRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,161,500
- Market Cap $136M
- Description
- Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-dr...